Roxatidine-d10 hemioxalate | CAS# 1794756-35-6 | Roxatidine internal standard

MedKoo Cat#: 464710 | Name: Roxatidine-d10 hemioxalate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Roxatidine-d10 is intended for use as an internal standard for the quantification of roxatidine by GC- or LC-MS. Roxatidine is a histamine H2 receptor antagonist and major active metabolite of roxatidine acetate.

Chemical Structure

Roxatidine-d10 hemioxalate

CAS#1794756-35-6

Theoretical Analysis

MedKoo Cat#: 464710

Name: Roxatidine-d10 hemioxalate

CAS#: 1794756-35-6

Chemical Formula: C19H18D10N2O7

Exact Mass:

Molecular Weight: 406.50

Elemental Analysis: C, 56.14; H, 9.42; N, 6.89; O, 27.55

Price and Availability

Size	Price	Availability	Quantity
1mg	USD 450.00	2 Weeks
5mg	USD 1,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Roxatidine-d10 hemioxalate; Roxatidine d10 hemioxalate;

IUPAC/Chemical Name

2-hydroxy-N-(3-(3-((piperidin-1-yl-d10)methyl)phenoxy)propyl)acetamide oxalate

InChi Key

SRDQKICJPUSODU-WPDGUVEOSA-N

InChi Code

InChI=1S/C17H26N2O3.C2H2O4/c20-14-17(21)18-8-5-11-22-16-7-4-6-15(12-16)13-19-9-2-1-3-10-19;3-1(4)2(5)6/h4,6-7,12,20H,1-3,5,8-11,13-14H2,(H,18,21);(H,3,4)(H,5,6)/i1D2,2D2,3D2,9D2,10D2;

SMILES Code

O=C(O)C(O)=O.O=C(CO)NCCCOC1=CC=CC(CN2C([2H])(C([2H])(C([2H])(C([2H])(C([2H])2[2H])[2H])[2H])[2H])[2H])=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Roxatidine acetate hydrochloride is a specific and competitive histamin H2-receptor antagonist, with IC50 of 3.2 μM. It inhibits gastric acid secretion and ulcer formation.

In vitro activity:

Results indicate that roxatidine ameliorated TNF-α- induced the phosphorylations of IKK, IκBα, and NF-κB p65 as well as nuclear translocation of NF-κB p65 and the transcriptional activity of NF-κB, suggesting that roxatidine abolished the activation of NF-κB signaling pathway. Roxatidine attenuated TNF-α- induced degradation of type II collagen by suppressing the expression of MMP-3 and MMP-13 in human chondrosarcoma cell line SW1353 cells. Reference: Biomed Pharmacother. 2017 Nov;95:1156-1160. https://pubmed.ncbi.nlm.nih.gov/28926925/

In vivo activity:

Roxatidine acetate HCl (RXA) may be a potential anti-atopic dermatitis (AD) candidate. RXA treatment significantly alleviated Dfb-induced AD skin symptoms by decreasing immunoglobulin E, histamine, and inflammatory cytokines levels. RXA effectively inhibited the expression of adhesive molecules and recovered the filaggrin expression in Dfb-induced AD skin lesions and TNF-α/IFN-γ-stimulated HaCaT keratinocytes. RXA upregulated the expression of aryl hydrocarbon receptor and sirtuin1. Reference: Front Pharmacol. 2021 Dec 24;12:797086. https://pubmed.ncbi.nlm.nih.gov/35002730/

Preparing Stock Solutions

The following data is based on the product molecular weight 406.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Ze R, Wang S, Xie M, Zhang B, Tang X, Li J. Roxatidine Attenuates Degradation of Extracellular Matrix. Biomed Pharmacother. 2017 Nov;95:1156-1160. doi: 10.1016/j.biopha.2017.08.130. Epub 2017 Sep 15. PMID: 28926925. 2. Cho EJ, An HJ, Shin JS, Choi HE, Ko J, Cho YW, Kim HM, Choi JH, Lee KT. Roxatidine suppresses inflammatory responses via inhibition of NF-κB and p38 MAPK activation in LPS-induced RAW 264.7 macrophages. J Cell Biochem. 2011 Dec;112(12):3648-59. doi: 10.1002/jcb.23294. PMID: 21809375. 3. Kang YM, Lee M, An HJ. New Potential of Roxatidine Acetate Hydrochloride on Atopic Dermatitis Mouse Model, Human Keratinocytes, and Human Skin Equivalent Model. Front Pharmacol. 2021 Dec 24;12:797086. doi: 10.3389/fphar.2021.797086. PMID: 35002730; PMCID: PMC8740129. 4. Ji L, Wang T, Tian L, Song H, Gao M. Roxatidine inhibits fibrosis by inhibiting NF‑κB and MAPK signaling in macrophages sensing breast implant surface materials. Mol Med Rep. 2020 Jan;21(1):161-172. doi: 10.3892/mmr.2019.10815. Epub 2019 Nov 12. PMID: 31746427; PMCID: PMC6896367.

In vitro protocol:

In vivo protocol:

1. Kang YM, Lee M, An HJ. New Potential of Roxatidine Acetate Hydrochloride on Atopic Dermatitis Mouse Model, Human Keratinocytes, and Human Skin Equivalent Model. Front Pharmacol. 2021 Dec 24;12:797086. doi: 10.3389/fphar.2021.797086. PMID: 35002730; PMCID: PMC8740129. 2. Ji L, Wang T, Tian L, Song H, Gao M. Roxatidine inhibits fibrosis by inhibiting NF‑κB and MAPK signaling in macrophages sensing breast implant surface materials. Mol Med Rep. 2020 Jan;21(1):161-172. doi: 10.3892/mmr.2019.10815. Epub 2019 Nov 12. PMID: 31746427; PMCID: PMC6896367.

1: Iwagami M, Kumazawa R, Miyamoto Y, Ito Y, Ishimaru M, Morita K, Hamada S, Tamiya N, Yasunaga H. Risk of Cancer in Association with Ranitidine and Nizatidine vs Other H2 Blockers: Analysis of the Japan Medical Data Center Claims Database 2005-2018. Drug Saf. 2021 Mar;44(3):361-371. doi: 10.1007/s40264-020-01024-0. Epub 2020 Nov 27. PMID: 33247391. 2: Qian Y, Huang J, Liu X, Liu T, Xue G, Gao P, Zhou X, Zhang Y, Chen J. Rapid oxidation of histamine H2-receptor antagonists by peroxymonosulfate during water treatment: Kinetics, products, and toxicity evaluation. Water Res. 2020 Oct 15;185:116278. doi: 10.1016/j.watres.2020.116278. Epub 2020 Aug 7. PMID: 32795718. 3: Ji L, Wang T, Tian L, Song H, Gao M. Roxatidine inhibits fibrosis by inhibiting NF‑κB and MAPK signaling in macrophages sensing breast implant surface materials. Mol Med Rep. 2020 Jan;21(1):161-172. doi: 10.3892/mmr.2019.10815. Epub 2019 Nov 12. PMID: 31746427; PMCID: PMC6896367. 4: Ze R, Wang S, Xie M, Zhang B, Tang X, Li J. Roxatidine Attenuates Degradation of Extracellular Matrix. Biomed Pharmacother. 2017 Nov;95:1156-1160. doi: 10.1016/j.biopha.2017.08.130. Epub 2017 Sep 15. PMID: 28926925. 5: Lee M, Lee NY, Chung KS, Cheon SY, Lee KT, An HJ. Roxatidine attenuates mast cell-mediated allergic inflammation via inhibition of NF-κB and p38 MAPK activation. Sci Rep. 2017 Jan 31;7:41721. doi: 10.1038/srep41721. PMID: 28139747; PMCID: PMC5282503. 6: Liu J, Sun D, He J, Yang C, Hu T, Zhang L, Cao H, Tong AP, Song X, Xie Y, He G, Guo G, Luo Y, Cheng P, Zheng Y. Gastroprotective effects of several H2RAs on ibuprofen-induced gastric ulcer in rats. Life Sci. 2016 Mar 15;149:65-71. doi: 10.1016/j.lfs.2016.02.045. Epub 2016 Feb 13. PMID: 26883979. 7: Sadek B, Alisch R, Buschauer A, Elz S. Synthesis and dual histamine H₁ and H₂ receptor antagonist activity of cyanoguanidine derivatives. Molecules. 2013 Nov 15;18(11):14186-202. doi: 10.3390/molecules181114186. PMID: 24248146; PMCID: PMC6269795. 8: Berzas Nevado JJ, Castañeda Peñalvo G, Rodríguez Dorado RM, Rodríguez Robledo V. Comparative validations of non-aqueous capillary electrophoresis and high- performance liquid chromatography methods for the simultaneous determination of histamine H2 receptor antagonists in human urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Mar 15;921-922:56-63. doi: 10.1016/j.jchromb.2013.01.020. Epub 2013 Jan 29. PMID: 23485449. 9: Nakai K, Niwa H, Kitayama M, Satoh Y, Hirota K. Effects of oral rehydration therapy on gastric volume and pH in patients with preanesthetic H2 antagonist. J Anesth. 2012 Dec;26(6):936-8. doi: 10.1007/s00540-012-1449-8. Epub 2012 Jul 20. PMID: 22814485. 10: Shikama N, Ichikawa T, Iwai T, Yamamoto H, Kida M, Koizumi W, Ishihara K. Different effects of two types of H2-receptor antagonists, famotidine and roxatidine, on the mucus barrier of rat gastric mucosa. Biomed Res. 2012 Feb;33(1):45-51. doi: 10.2220/biomedres.33.45. PMID: 22361886. 11: Nakamura H, Kawashima H, Azuma R, Sato I, Nagao K, Miyazawa K. Pharmacokinetics of the H(2) blocker roxatidine acetate hydrochloride in pediatric patients, in comparison with healthy adult volunteers. Drug Metab Pharmacokinet. 2012;27(4):422-9. doi: 10.2133/dmpk.dmpk-11-rg-112. Epub 2012 Jan 31. PMID: 22293541. 12: Iida H, Kato S, Sekino Y, Sakai E, Uchiyama T, Endo H, Hosono K, Sakamoto Y, Fujita K, Yoneda M, Koide T, Takahashi H, Tokoro C, Goto A, Abe Y, Kobayashi N, Kubota K, Gotoh E, Maeda S, Nakajima A, Inamori M. Early effects of oral administration of omeprazole and roxatidine on intragastric pH. J Zhejiang Univ Sci B. 2012 Jan;13(1):29-34. doi: 10.1631/jzus.B1100078. PMID: 22205617; PMCID: PMC3251749. 13: Palileo C, Kaunitz JD. Gastrointestinal defense mechanisms. Curr Opin Gastroenterol. 2011 Oct;27(6):543-8. doi: 10.1097/MOG.0b013e32834b3fcb. PMID: 21897225. 14: Maheshwari A, Sharma M, Sharma D. Investigation of the binding of roxatidine acetate hydrochloride with cyclomaltoheptaose (β-cyclodextrin) using IR and NMR spectroscopy. Carbohydr Res. 2011 Sep 27;346(13):1809-13. doi: 10.1016/j.carres.2011.07.003. Epub 2011 Jul 18. PMID: 21816394. 15: Cho EJ, An HJ, Shin JS, Choi HE, Ko J, Cho YW, Kim HM, Choi JH, Lee KT. Roxatidine suppresses inflammatory responses via inhibition of NF-κB and p38 MAPK activation in LPS-induced RAW 264.7 macrophages. J Cell Biochem. 2011 Dec;112(12):3648-59. doi: 10.1002/jcb.23294. PMID: 21809375. 16: Imaeda H, Hosoe N, Suzuki H, Saito Y, Ida Y, Nakamura R, Iwao Y, Ogata H, Hibi T. Effect of lansoprazole versus roxatidine on prevention of bleeding and promotion of ulcer healing after endoscopic submucosal dissection for superficial gastric neoplasia. J Gastroenterol. 2011 Nov;46(11):1267-72. doi: 10.1007/s00535-011-0447-1. Epub 2011 Jul 30. PMID: 21805066. 17: Hirota K, Kudo M, Hashimoto H, Kushikata T. A marked increase in gastric fluid volume during cardiopulmonary bypass. J Clin Biochem Nutr. 2011 Jul;49(1):16-9. doi: 10.3164/jcbn.10-101. Epub 2011 Apr 26. PMID: 21765601; PMCID: PMC3128360. 18: Nevado JJ, Peñalvo GC, Dorado RM. Evaluation of non-aqueous capillary zone electrophoresis for the determination of histamine H2 receptor antagonists in pharmaceuticals. Anal Sci. 2011;27(4):427. doi: 10.2116/analsci.27.427. PMID: 21478620. 19: Ohashi A, Saiki M, Okuyama R. Psoriasiform eruption localized to a previously irradiated area. Acta Derm Venereol. 2011 Jun;91(4):469. doi: 10.2340/00015555-1058. PMID: 21336472. 20: Agrawal SS, Jose MA. Anti-ovulatory activity of H2 receptor blockers in albino rabbits--a preliminary study. Eur J Contracept Reprod Health Care. 2011 Apr;16(2):142-6. doi: 10.3109/13625187.2010.548882. Epub 2011 Jan 31. PMID: 21281096.